Samenvatting: Incyte maakt bekend dat meer dan 20 abstracts zijn geselecteerd voor presentatie op het congres van de European Hematology Association (EHA) in 2026
Wednesday, May 13, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Incyte announced that more than 20 abstracts have been selected for presentation at the European Hematology Association (EHA) conference in 2026. This significant participation underscores Incyte's ongoing research and contributions to the field of hematology. The event is expected to provide a platform for sharing important findings.
Price reaction · baseline $99.13 (2026-05-12 close) · hit after-hours · clean, no other INCY news in the window
day 0 close
-0.3%
Market Sentiment Analysis
POSITIVE FACTORS
Incyte has over 20 abstracts selected for presentation.
The presentation at EHA highlights Incyte's research efforts.
Participation in a major conference showcases Incyte's commitment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+44%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
INCB013739
Phase 2 · Type 2 Diabetes
Full Press Release Details
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) heeft vandaag bekendgemaakt dat gegevens uit belangrijke programma’s binnen zijn hematologie- en oncologie-divisies zullen worden gepresenteerd tijdens het congres van de European Hematology Association (EHA) 2026, dat van 11 tot en met 14 juni 2026 plaatsvindt in Stockholm, Zweden.
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.
Frequently Asked Questions
How many abstracts did Incyte have selected for EHA 2026?
Incyte had more than 20 abstracts selected for presentation.
What is the significance of the EHA conference for Incyte?
The EHA conference provides a platform for Incyte to showcase its research.